SOT 57th Annual Meeting and ToxExpo 2018 - Insphero

SOT 57th Annual Meeting and ToxExpo 2018


Mar 11 - 15, 2018

Predict DILI with Confidence

jump to section

Meet InSphero Toxicology Experts at SOT 2018 to learn how you can screen for toxic compounds earlier with 3D™ InSight assay ready models.

  • Achieve 2X sensitivity in DILI prediction without sacrificing specificity
  • Minimize risks late-stage market withdrawal
  • Rely on ISO 9001:2015 quality-controlled microtissues
  • Reduce animal testing with a pharma-validated 3D liver model

Schedule a Meeting

Enabling sensitive DILI prediction through the presence of DILI-relevant biological pathways and exposure settings (1-5)

Tease out Mechanisms of Toxicity

Talk to our team at SOT to discuss how we can work for you. 3D InSight™ Toxicology Services combine the predictive power of our physiologically relevant liver models with the applications expertise of our scientific staff.

  • Standardized DILI Screening
  • Custom Mechanistic & Investigative Studies
  • Mitochondrial Tox
  • Pancreatic Endocrine Toxicity

Conference Detail

  • Conference Dates: March 11-15, 2018
  • Venue: Henry B. Gonzalez Convention Center, San Antonio, TX USA
  • Booth: 1313

jump to section
jump to section

Oral Presentations

Exhibitor Hosted Session

Monday, March 12, 1:30 – 2:30 PM, Room 217D
Validation of 3D Human Liver Microtissues for Enhanced DILI Prediction and Investigation of Mechanisms of Hepatotoxicity
3D microtissues have emerged as promising tools to assess mechanisms of hepatotoxicity, as they demonstrate enhanced liver phenotype and function. Here we present the most comprehensive evaluation by pharma to date demonstrating their utility for enhanced DILI prediction, as well as application examples for studying mechanistic aspects of hepatotoxicity.

Exhibitor Hosted Session

Tuesday, March 13, 9 – 10 AM, Room 217D
A Novel 3D Microtissue-based Platform for Studying Liver Fibrosis
We will share the characterization of a 3D Human Liver Fibrosis Model as a novel tool to study liver fibrosis, suitable for high-throughput efficacy testing of anti-fibrotic drugs. The disease model consists only of primary cell material for more physiologically relevant screening hits.

Poster Presentations

Session: New Models and Biomarkers for Liver Damage

Monday, March 12, 10:45 AM – 12:15 PM, Exhibit Hall
Poster Number: 1368/P466
Presenting Author: Julie Harney, Pfizer
Title: Co-Culture of Primary Human 3D Hepatic Spheroids with Non-Parenchymal Cells Allows for Detection of Immune-Related Drug-Induced Liver Injury Compounds

Session: New Models and Biomarkers for Liver Damage

Monday, March 12, 10:45 AM – 12:15 PM, Exhibit Hall
Poster Number: 1361/P459
Presenting Author: Radina Kostadinova, InSphero
Title: A Novel 3D Human Liver Fibrosis Model for Anti-Fibrotic Drug Discovery and Safety Testing

Session: New Models and Biomarkers for Liver Damage

Monday, March 12, 10:45 AM – 12:15 PM, Exhibit Hall
Poster Number: 1378/P476
Presenting Author: Theo de Kok, Maastricht University
Title: Impact of Inflammatory Conditions on Acetaminophen-Induced Liver Injury in a 3D Human Liver Model

InSphero In-Booth Posters

March 12-14, during exhibit hours, ToxExpo Booth 1313

  • Akura™ Flow: A Microfluidic Multi-Tissue Platform Engineered for 3D InSight™ Microtissues
  • Akura™ 384: A High-Content Platform Engineered for 3D InSight™ Microtissues
  • Diseased human 3D microtissues as building blocks for complex metabolic in vitro systems
  • Co-culture of Primary Human 3D Hepatic Microtissues with Non-Parenchymal Cells allows for Detection of Immune Related Drug-Induced Liver Injury Compounds
  • A Novel 3D Human Liver Fibrosis Model for anti-fibrotic Drug discovery and Testing
  • Steatotic Liver Microtissues for the Study of Toxic Effects in Compromised Livers